{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7"},{"groupId":"OG001","value":"99.1"}]}],"title":"Percentage of participants with at least one AE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.4"},{"groupId":"OG001","value":"25.9"}]}],"title":"Percentage of participants with at least one SAE"}],"denoms":[{"counts":[{"groupId":"OG000","value":"217"},{"groupId":"OG001","value":"432"}],"units":"Participants"}],"description":"Investigator text for AEs is coded using MedDRA version 25.1","groups":[{"description":"Participants will receive placebo matching to atezolizumab via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg/m\\^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG000","title":"Placebo and Paclitaxel"},{"description":"Participants will receive atezolizumab at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 (± 3 days) of every 28-day cycle along with paclitaxel administered at a dose of 90 mg per square meter (mg/m\\^2) via IV infusion on Days 1, 8, and 15 of every 28-day cycle until disease progression or unacceptable toxicity.","id":"OG001","title":"Atezolizumab and Paclitaxel"}],"paramType":"NUMBER","populationDescription":"Safety-evaluable population: participants who received any amount of any study drug. For all safety, PK and immunogenicity analyses, participants were grouped according to the treatment actually received, including cases in which atezolizumab was received in error.","reportingStatus":"POSTED","timeFrame":"From Day 1 From baseline up to 64 months","title":"Percentage of Participants With Adverse Events (AEs) and Serious AEs (SAEs)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}